

Not for distribution to United States newswire services or for dissemination in the United States.

The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

## MERUS LABS INTERNATIONAL INC.

MERUS LABS INTERNATIONAL INC. ANNOUNCES PRIVATE PLACEMENT AND BRIDGE LOAN

VANCOUVER, April 25, 2011

(CNSX: MR)

**Merus Labs International Inc.** ("Merus" or the "Company") has agreed to a non-brokered private placement with Primary Capital Inc. to issue up to 2.5 million units at the price of 21 cents per unit, for maximum gross proceeds of \$525,000.

The units will consist of one common share of the Company and one share purchase warrant. Each warrant shall entitle the holder to purchase an additional common share of the Company at a price of 40 cents per share for a period of two years from the date of closing.

A finder's fee in connection with the offering was paid, consisting of a finder's unit equal to 10 per-cent of the number of units referred. Each finder's option unit is exercisable into one unit at a price of 21 cents per unit for a period of two years from the date of closing. All securities issued pursuant to this offering are subject to a four-month hold period from the date of closing.

In addition, the Company has agreed to a short term financing facility with Envoy Capital Group Inc. and other parties in the aggregate amount of \$3.5 million for a six month term. No finder's fees are payable in connection with the short term financing facility.

The proposed financings are expected to close on or before April 29, 2011.

Proceeds from the financings will be used primarily to acquire previously announced (Press Release dated April 18, 2011) products for the Canadian market from a multinational pharmaceutical company.

### **About Merus Labs International Inc.**

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

### **Forward-looking Statements:**

*This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.*

For further information please contact:

Dr. Ahmad Doroudian, Chief Executive Officer

Merus Labs International Inc.  
Tel: (604) 805-7783  
adoroudian@meruslabs.com